4 completed, 1 terminated, 1 unknown. 6 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 4, Terminated 1, Unknown 1 |
| Phase 1 | 2 | Completed 1, Terminated 1 |
| Phase 3 | 1 | Completed 1 |
Follow casirivimab: new trials by email Literature Review of casirivimab trials Research Report on casirivimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| COVID-19 Study to Evaluate Safety, Tolerability, and Efficacy of REGN14256+Imdevimab for the Treatment of COVID-19 Adult and Adolescent Patients Without Risk Factors for Progression to Severe Disease REGN14256, imdevimab, casirivimab + imdevimab - SARS-CoV-2 | Phase 1 / Phase 2 | Terminated | Regeneron Pharmaceuticals | 25 | 2021-11-08 | 2025-10-28 |
| COVID-19 Study to Assess Immunogenicity, Safety, and Tolerability of Moderna mRNA-1273 Vaccine Administered With Casirivimab+Imdevimab in Healthy Adult Volunteers casirivimab+imdevimab, Moderna mRNA-1273 vaccine - Healthy, Chronic Stable Illness | Phase 2 | Completed | Regeneron Pharmaceuticals | 295 | 2021-04-29 | 2025-10-20 |
| COVID-19 Study Assessing the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Adult Outpatients With SARS-CoV-2 Infection REGN10933+REGN10987 combination therapy, Placebo - COVID-19 | Phase 2 | Completed | Regeneron Pharmaceuticals | 1149 | 2020-12-15 | 2022-04-08 |
| Use of Monoclonal Antibodies for the Treatment of Mild to Moderate COVID-19 in Non-Hospitalized Setting BAMLANIVIMAB, CASIRIVIMAB, IMDEVIMAB - Covid19 | Phase 2 | Unknown | Sohail Rao | 1000 | 2020-11-20 | 2022-03-29 |
| ACTIV-2: A Study for Outpatients With COVID-19 bamlanivimab 7000mg, BRII-196+BRII-198, AZD7442 (IV) - Coronavirus, Covid19 | Phase 2 / Phase 3 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 4044 | 2020-08-19 | 2024-08-02 |
| Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19 REGN10933+REGN10987 combination therapy, Placebo - COVID-19 | Phase 1 / Phase 2 | Completed | Regeneron Pharmaceuticals | 2252 | 2020-06-10 | 2023-01-27 |
COVID-19 (5) · Coronavirus Infections (4) · Coronaviridae Infections (1) · Nidovirales Infections (1) · RNA Virus Infections (1) · Respiratory Distress Syndrome (1) · Severe Acute Respiratory Syndrome (1) · Virus Diseases (1)
Regeneron Pharmaceuticals (4) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Sohail Rao (1)
United States (6) · Brazil (2) · Mexico (2) · Argentina (1) · Canada (1) · Chile (1) · Guatemala (1) · Moldova (1) · Philippines (1) · Puerto Rico (1) · Romania (1) · South Africa (1)
David Smith, MD, MAS (1) · Sohail Rao, MD (1)
PMID 34473343, PMID 35713300, PMID 34981077, PMID 35793677, PMID 35797235, PMID 35895508, PMID 35969402, PMID 35995785, PMID 36210483, PMID 36255239, PMID 36289399, PMID 36301549, PMID 36378539, PMID 36467293, PMID 36661240, PMID 36802755, PMID 37068272, PMID 37099295, PMID 37229174, PMID 37279602, PMID 37650230, PMID 37650232, PMID 37650233, PMID 37650236, PMID 37855026, PMID 39018444, PMID 39028902, PMID 39236733, PMID 42148571